Cargando…

Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial

BACKGROUND: The addition of plasmid cytokine adjuvants, electroporation, and live attenuated viral vectors may further optimize immune responses to DNA vaccines in heterologous prime-boost combinations. The objective of this study was to test the safety and tolerability of a novel prime-boost vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elizaga, Marnie L., Li, Shuying S., Kochar, Nidhi K., Wilson, Gregory J., Allen, Mary A., Tieu, Hong Van N., Frank, Ian, Sobieszczyk, Magdalena E., Cohen, Kristen W., Sanchez, Brittany, Latham, Theresa E., Clarke, David K., Egan, Michael A., Eldridge, John H., Hannaman, Drew, Xu, Rong, Ota-Setlik, Ayuko, McElrath, M. Juliana, Hay, Christine Mhorag
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6147413/ https://www.ncbi.nlm.nih.gov/pubmed/30235286 http://dx.doi.org/10.1371/journal.pone.0202753

Ejemplares similares

Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults
por: Kalams, Spyros A., et al.
Publicado: (2012)

Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy
por: Youn, Hyewon, et al.
Publicado: (2015)

Double conjugation strategy to incorporate lipid adjuvants into multiantigenic vaccines
por: Hussein, Waleed M., et al.
Publicado: (2016)

MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load
por: Janes, Holly, et al.
Publicado: (2012)

Immunogenicity of Multiple Doses of pDNA Vaccines against SARS-CoV-2
por: Almansour, Iman, et al.
Publicado: (2021)

Exploring the Fate of Antibody-Encoding pDNA after Intramuscular Electroporation in Mice
por: Cuypers, Marie-Lynn, et al.
Publicado: (2023)

Dose-dependent inhibition of Gag cellular immunity by Env in SIV/HIV DNA vaccinated macaques
por: Valentin, Antonio, et al.
Publicado: (2015)

Vaccination with MVA/HIV induces differential recruitment of monocyte subsets into the circulation and monocyte-specific transcriptional programs
por: Andersen-Nissen, E, et al.
Publicado: (2012)

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)
por: Fuchs, Jonathan D., et al.
Publicado: (2015)

In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers
por: Vasan, Sandhya, et al.
Publicado: (2011)

COVID-19 vaccination and HIV-1 acquisition – Authors’ reply
por: Buchbinder, Susan P, et al.
Publicado: (2022)

P08-06 LB. A genome-wide association study of host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the STEP trial
por: Fellay, J, et al.
Publicado: (2009)

Comparison of DNA vaccines producing HIV-1 Gag and LAMP/Gag chimera in rhesus macaques reveals antigen-specific T-cell responses with distinct phenotypes
por: Valentin, Antonio, et al.
Publicado: (2009)

Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques
por: Valentin, Antonio, et al.
Publicado: (2022)

Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine
por: Margalith, Michal, et al.
Publicado: (2006)

Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP(®) DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults
por: Edupuganti, Srilatha, et al.
Publicado: (2020)

The Safety and Immunogenicity of GTU(®)MultiHIV DNA Vaccine Delivered by Transcutaneous and Intramuscular Injection With or Without Electroporation in HIV-1 Positive Subjects on Suppressive ART
por: Haidari, G., et al.
Publicado: (2019)

Nucleophile responsive charge-reversing polycations for pDNA transfection
por: Lewis, Reece W., et al.
Publicado: (2023)

An Improved Tobacco Mosaic Virus (TMV)-Conjugated Multiantigen Subunit Vaccine Against Respiratory Tularemia
por: Mansour, Ahd A., et al.
Publicado: (2018)

HIV-1 p24(gag) Derived Conserved Element DNA Vaccine Increases the Breadth of Immune Response in Mice
por: Kulkarni, Viraj, et al.
Publicado: (2013)

Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime
por: Bauer, A, et al.
Publicado: (2012)

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults
por: Mpendo, Juliet, et al.
Publicado: (2015)

Natural steroid-based cationic copolymers cholesterol/diosgenin-r-PDMAEMAs and their pDNA nanoplexes: impact of steroid structures and hydrophobic/hydrophilic ratios on pDNA delivery
por: Wang, Zhao, et al.
Publicado: (2021)

P17-25. A model for coverage of T-cell HIV vaccines: where are we and where do we need to be?
por: Self, S, et al.
Publicado: (2009)

First-in-human phase I clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventive HIV-1 vaccine
por: Fuchs, JD, et al.
Publicado: (2012)

Anti-tumor activity of a T-helper 1 multiantigen vaccine in a murine model of prostate cancer
por: Cecil, Denise L., et al.
Publicado: (2022)

Amino-acid functionalized porous silicon nanoparticles for the delivery of pDNA
por: Chaix, Arnaud, et al.
Publicado: (2019)

Characterization of transgene expression and pDNA distribution of the suctioned kidney in mice
por: Oyama, Natsuko, et al.
Publicado: (2017)

Enhancing pDNA Delivery with Hydroquinine Polymers by Modulating Structure and Composition
por: Roy, Punarbasu, et al.
Publicado: (2023)

Novel codon-optimized GM-CSF gene as an adjuvant to enhance the immunity of a DNA vaccine against HIV-1 gag
por: Qiu, Jian-Tai, et al.
Publicado: (2006)

Nedd4-Mediated Increase in HIV-1 Gag and Env Proteins and Immunity following DNA-Vaccination of BALB/c Mice
por: Lewis, Brad, et al.
Publicado: (2014)

HIV-1 Gag co-opts a cellular complex containing DDX6, a helicase that facilitates capsid assembly
por: Reed, Jonathan C., et al.
Publicado: (2012)

Heterologous prime-boost vaccination with DNA and MVA vaccines, expressing HIV-1 subtype C mosaic Gag virus-like particles, is highly immunogenic in mice
por: Chapman, Ros, et al.
Publicado: (2017)

Expression of concern: Natural steroid-based cationic copolymers cholesterol/diosgenin-r-PDMAEMAs and their pDNA nanoplexes: impact of steroid structures and hydrophobic/hydrophilic ratios on pDNA delivery
por: Wang, Zhao, et al.
Publicado: (2023)

FtlA and FtlB Are Candidates for Inclusion in a Next-Generation Multiantigen Subunit Vaccine for Lyme Disease
por: Camire, Andrew C., et al.
Publicado: (2022)

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial
por: Rouphael, Nadine G., et al.
Publicado: (2019)

DNA/MVA Vaccines for HIV/AIDS
por: Iyer, Smita S., et al.
Publicado: (2014)

DNA Immunization for HIV Vaccine Development
por: Chen, Yuxin, et al.
Publicado: (2014)

An Update on the HIV DNA Vaccine Strategy
por: Hokello, Joseph, et al.
Publicado: (2021)

Chitosan IFN-γ-pDNA Nanoparticle (CIN) Therapy for Allergic Asthma
por: Kumar, Mukesh, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_1p693rmuik9p9i1g7t98ggrvnh